Literature DB >> 9788258

Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors.

T Fukuda1, E Ichimura, T Shinozaki, T Sano, K Kashiwabara, T Oyama, T Nakajima, T Nakamura.   

Abstract

To understand the interaction between hepatocyte growth factor (HGF) and its receptor c-Met on various bone and soft tissue tumors, their expressions were investigated by western blot analysis, immunohistochemistry and enzyme immunoassay. Western blot analysis revealed that c-Met protein was expressed in 21 (38.8%) of 54 tumors, which detailed to seven (25.9%) of 27 bone tumors and 14 (51.8%) of 27 soft tissue tumors. Most malignant fibrous histiocytomas (MFH) and all neurofibromas expressed c-Met protein. The highest expression of c-Met protein was seen in a case of biphasic synovial sarcoma, where its immunoreactivity was localized only on the epithelial component and not on the sarcomatous component. By enzyme immunoassay for HGF, all but one MFH showed HGF production and the mean level of HGF was the highest among the tumors investigated. Neurofibromas and osteosarcomas had the next highest mean levels of HGF production, respectively. Coexpression of HGF and c-Met was observed in 19 (35.2%) of 54 tumors and was frequently observed in neurofibroma, followed by MFH and synovial sarcoma. Although the mode of interaction between HGF and c-Met varies among the various bone and soft tissue tumors including MFH, their signaling system may play an important role in the development and progression of bone and soft tissue tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788258     DOI: 10.1111/j.1440-1827.1998.tb03834.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  21 in total

1.  Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Authors:  Trent R Hummel; Walter J Jessen; Shyra J Miller; Lan Kluwe; Victor F Mautner; Margaret R Wallace; Conxi Lázaro; Grier P Page; Paul F Worley; Bruce J Aronow; Elizabeth K Schorry; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

2.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.

Authors:  Sharon Moshitch-Moshkovitz; Galia Tsarfaty; Dafna W Kaufman; Gideon Y Stein; Keren Shichrur; Eddy Solomon; Robert H Sigler; James H Resau; George F Vande Woude; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

Review 4.  Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.

Authors:  Patrick J Messerschmitt; Ashley N Rettew; Robert E Brookover; Ryan M Garcia; Patrick J Getty; Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2008-07-08       Impact factor: 4.176

5.  miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.

Authors:  Laura Pazzaglia; Chiara Novello; Amalia Conti; Serena Pollino; Piero Picci; Maria Serena Benassi
Journal:  Cell Oncol (Dordr)       Date:  2016-11-29       Impact factor: 6.730

6.  Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

Authors:  Keila E Torres; Quan-Sheng Zhu; Katelynn Bill; Gonzalo Lopez; Markus P Ghadimi; Xianbiao Xie; Eric D Young; Juehui Liu; Theresa Nguyen; Svetlana Bolshakov; Roman Belousov; Suizhau Wang; Guy Lahat; Jun Liu; Belinda Hernandez; Alexander J Lazar; Dina Lev
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

7.  Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling.

Authors:  Yi Guo; Jun Xie; Elyssa Rubin; Ya-Xiong Tang; Fritz Lin; Xiaolin Zi; Bang H Hoang
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density.

Authors:  Cornelius Kuhnen; Thomas Muehlberger; Maria Honsel; Edina Tolnay; Hans Ulrich Steinau; Klaus-Michael Müller
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-09       Impact factor: 4.553

Review 9.  MET: a promising anticancer therapeutic target.

Authors:  Solange Peters; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2012-05-08       Impact factor: 66.675

10.  Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.

Authors:  Eric P Rahrmann; Branden S Moriarity; George M Otto; Adrienne L Watson; Kwangmin Choi; Margaret H Collins; Margaret Wallace; Beau R Webber; Colleen L Forster; Anthony E Rizzardi; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Am J Pathol       Date:  2014-05-13       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.